Date of Award

Spring 5-17-2024

Document Type

Open Access Thesis

Degree Name

Master of Medical Science (MMSc)

First Advisor

Nicola Santoro, MD, PhD

Abstract

Metabolic dysfunction-associated steatohepatitis is a severe form of liver disease marked by fat accumulation, inflammation, and scarring, often advancing to cirrhosis. Currently, there are limited therapies to treat this condition. Empagliflozin, a Sodium-glucose cotransporter 2 Inhibitor, that blocks renal reabsorption of glucose, has shown efficacy in reducing liver fat accumulation. However, there are currently no large-scale studies have investigated the effect of empagliflozin in treating metabolic dysfunction-associated steatohepatitis using histological findings. We propose a randomized controlled trial to study the effect of empagliflozin on the resolution of Metabolic dysfunction-associated steatohepatitis. We will recruit participants with histology-confirmed metabolic dysfunction-associated steatohepatitis and reassess the resolution of liver histology after 48 weeks of empagliflozin intervention This study aims to increase our knowledge about the effectiveness of empagliflozin in treating metabolic dysfunction-associated steatohepatitis which can reduce the morbidity and mortality caused by the disease.

Comments

This is an open access thesis.

Open Access

This Article is Open Access

Share

COinS